Printer Friendly

Merck to invest EUR80m in new pharmaceutical manufacturing facility.

M2 EQUITYBITES-November 18, 2013-Merck to invest EUR80m in new pharmaceutical manufacturing facility(C)2013 M2 COMMUNICATIONS

Merck, an international developer, manufacturer and distributor of pharmaceuticals, is investing EUR80m in a new pharmaceutical manufacturing facility.

It was reported on Friday that the facility is to be situated in the Nantong Economical Technological Development Area in the Greater Shanghai region (Yangtze River Delta area). It will concentrate on the bulk production and packaging of Glucophage, Concor and Euthyrox, Merck's brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively.

The facility will accommodate all aspects of the life science industry and will cover an area of 40,000 square metre with a possible 20,000 square metre extension. The company will start construction of the facility in 2014, and it is scheduled to complete construction in 2016 with commercial production to start in 2017.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 18, 2013
Previous Article:Indian Elder Pharma to speed up sale to Sanofi under debt pressure - report.
Next Article:Eli Lilly and Company to invest USD700m in global insulin manufacturing capacity.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters